Skip to main content
Explore URMC
menu
URMC / Research / Clinical Trials / Study Details

CLEU15006 / S1318 / Kristen O'Dwyer

Research Question:
What are the good and/or bad effects of adding the drug blinatumomab to different doses of standard combinations of chemotherapy drugs? Can standard therapy drugs can be given at lower doses (when given with blinatumomab) in order to reduce overall side effects and be effective in treating ALL?

Basic Study Information

Purpose:
This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with acute lymphoblastic leukemia. Immunotherapy with monoclonal antibodies, such as blinatumomab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Drugs used in chemotherapy, such as prednisone, vincristine sulfate, methotrexate, and mercaptopurine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving blinatumomab with combination chemotherapy or dasatinib and prednisone may kill more cancer cells.

Location: Cancer Center
Study Web URL:  https://clinicaltrials.gov/ct2/show/NCT02143414?term=S1318&rank=1
Study Reference #: CLEU-15006

Lead Researcher (Principal Investigator)

Lead Researcher:  Kristen O'Dwyer

Study Contact Information

Study Coordinator: Amber Johnson
Email: amber_johnson@urmc.rochester.edu

Additional Study Details

Learn More About These Conditions

More information about Acute lymphoblastic leukemia [ALL]

Return to Search